Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428635 · ClinicalTrials.gov registry record · Phase 2
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
A Phase 2 study of Primary Myelofibrosis and Thrombocytopenia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01428635 is a Phase 2 study of Primary Myelofibrosis and Thrombocytopenia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01428635, a Phase 2 study of Primary Myelofibrosis and Thrombocytopenia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II/III trial studies how well eltrombopag olamine works in treating thrombocytopenia in patients with chronic myeloid leukemia or myelofibrosis receiving tyrosine kinase inhibitor therapy. Eltrombopag olamine may cause the body to make platelets after receiving treatment for chronic myeloid leukemia or myelofibrosis.
Conditions Studied
Interventions
- DRUG Eltrombopag Olamine
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-01-13 |
| Est. Completion | 2022-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01428635
The ClinicalTrials.gov registry entry for NCT01428635 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (82% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Eltrombopag Olamine is the first listed.
NCT01428635 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01428635 about?
NCT01428635 is a clinical study titled "Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy". This phase II/III trial studies how well eltrombopag olamine works in treating thrombocytopenia in patients with chronic myeloid leukemia or myelofibrosis receiving tyrosine kinase inhibitor therapy. Eltrombopag olamine may cause the body to make platelets after receiving treatment for chronic myelo...
What is the current status of trial NCT01428635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2012-01-13. Estimated completion is 2022-01-03.
What conditions does trial NCT01428635 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Thrombocytopenia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive.
What interventions are being tested in trial NCT01428635?
The interventions under investigation include: Eltrombopag Olamine (DRUG).
Who is sponsoring clinical trial NCT01428635?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01428635 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.